Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mavorixafor in chronic neutropenic disorders with recurrent or serious infections
2023-508482-32-00Phase 3Authorised
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in neutropenia, congenital agranulocytosis (SCN) and primary autoimmune neutropenia (AIN) comparing Mavorixafor with Placebo (2 arms). Primary endpoints: Annualized infection rate, Proportion of ANC responders and 1 more. Planned start Jul 2024; status: authorised.
02
Drugs
mavorixafor
03
Conditions
neutropeniacongenital agranulocytosis (SCN)primary autoimmune neutropenia (AIN)
Beyond the preview
Go deeper on 2023-508482-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508482-32-00.